Expansion of the European and Other Businesses through the Transfer of the Marketing Rights for Dificlir Tablets
First written in FY2021-Q3. 8 of 14 entries say "Advanced", first in FY2022-Q1. Latest entry: 2026-08-06.
Zeria Pharmaceutical moved to the "Worse" side of this theme in 2026.
0 other companies' latest entry also says "Worsened".
- 2026-08-06WorsenedEarnings
「今後の後発品参入可能性が高まったことから耐用年数を短縮し、将来にわたり変更しております。この結果、当第１四半期連結累計期間の営業利益、経常利益及び税金等調整前四半期純利益はそれぞれ388,569千円減少しております。」
ディフィクリアの後発品参入リスクが、販売権の耐用年数短縮および3億8,856万9千円の利益減少として具体化した。 - FY2026WorsenedAnnual report
「During the period covered by the 12th Medium-Term Management Plan, generic competition is expected because the patent for Dificlir, which drove performance under the previous plan, will expire.」
While Dificlir sales have continued to grow in Europe, the entry of generic products following patent expiry was explicitly identified as a specific business risk during the period of the next medium-term plan. - FY2026-H1Slight decline in sales of a major productAnnual report
「Dificlir 9,852,150 － 9,852,150 － 9,852,150」
According to the revenue breakdown, Dificlir sales edged down from ¥9,889,515 thousand in the interim period of the previous year to ¥9,852,150 thousand. - FY2025AdvancedAnnual report
「Dificlir has steadily expanded its market, supported by its recommendation as a first-line treatment in European infectious disease treatment guidelines, as a result of actively deploying sales resources and thoroughly raising product awareness, and sales grew sharply across major European countries. Further growth is expected in Germany, the UK and other large markets, and the Company will strengthen its sales activities.」
Dificlir sales grew sharply in France and across major European countries, and the Company indicated that it would strengthen sales activities in Germany, the UK and other markets. - FY2025-H1AdvancedAnnual report
「Sales of Dificlir (domestic brand name: Dafclir) increased substantially in countries including France, Germany and the United Kingdom.」
Dificlir sales continued to expand in Europe, with substantial growth in Germany and the UK in addition to the previously France-centred progress. - FY2024AdvancedAnnual report
「Dificlir has steadily expanded its market, supported by its recommendation as a first-line treatment in European infectious disease treatment guidelines, as a result of actively deploying sales resources and thoroughly raising product awareness. Sales grew particularly sharply in France. Further growth is expected in Germany, the UK and Spain, where the markets are larger, and the Company will strengthen its sales activities.」
Dificlir sales grew sharply in Europe, particularly in France, and the Company indicated that it would strengthen sales activities in Germany, the UK and Spain. - FY2024-Q1AdvancedAnnual report
「As a result of continuing to actively deploy sales resources for Dificlir, a treatment for Clostridioides difficile infection, in overseas markets, sales increased substantially in countries including France, Spain and the United Kingdom. In Japan, the company also took over the marketing authorisation from Astellas Pharma Inc. in April 2023 and began sales under the domestic brand name Dafclir.」
In addition to continued sales growth in major European countries, the Company reported as a first-quarter result that it had progressed in Japan to assuming the marketing authorisation and launching sales in April 2023. - FY2023AdvancedAnnual report
「As part of its active pursuit of M&A and alliances to strengthen the Group's business platform, the Group also assumed the marketing authorisation for Dificlir in Japan from Astellas Pharma Inc. in April 2023 and began sales. The product is marketed in Japan under the name DAFCLIR.」
In addition to expanding Dificlir sales in Europe, the Company progressed in Japan to assuming the marketing authorisation and launching sales in April 2023. - FY2023-Q3RestatedAnnual report
「Dificlir, a treatment for Clostridioides difficile infection, is recommended as a first-line treatment in European infectious disease treatment guidelines. As a result of actively deploying sales resources, sales increased substantially.」
The Company continues to deploy sales resources and work to expand Dificlir sales against the backdrop of its recommendation in treatment guidelines. - FY2023-Q2AdvancedAnnual report
「Dificlir, a treatment for Clostridioides difficile infection, is recommended as a first-line treatment in European infectious disease treatment guidelines. As a result of actively deploying sales resources, sales increased substantially.」
While Dificlir was recommended as a first-line treatment in European infectious disease treatment guidelines, sales grew substantially as the Company actively deployed sales resources. - FY2023-Q1AdvancedAnnual report
「Dificlir, a treatment for Clostridioides difficile infection, is recommended as a first-line treatment in European infectious disease treatment guidelines. As a result of actively deploying sales resources, sales increased substantially.」
While Dificlir was recommended as a first-line treatment in European infectious disease treatment guidelines, sales grew substantially as the Company actively deployed sales resources. - FY2022-Q3RestatedAnnual report
「Dificlir, a treatment for Clostridioides difficile infection for which the marketing rights in Europe, the Middle East and other regions were transferred from Astellas Pharma Europe Ltd. in November 2020, has completed the transfer procedures for marketing rights in major European countries and is making a significant contribution to sales.」
The transfer procedures for Dificlir in major European countries have been completed and the product continues to contribute to sales, with monetisation progressing following the acquisition of the rights. - FY2022-Q1AdvancedAnnual report
「The Clostridioides difficile infection treatment DIFICLIR, for which we succeeded to the manufacturing and marketing rights in Europe, the Middle East and other regions from Astellas Pharma Europe Ltd. in November last year, has completed the succession procedures in major European countries and is already making a significant contribution to sales.」
The procedures for transferring the marketing rights for Dificlir in major European countries were completed, and the product moved into the sales and monetisation phase following the acquisition of the rights. - FY2021-Q3First statedAnnual report
「At a meeting of its board of directors held on 19 November 2020 (local time), the Company's wholly owned subsidiary Tillotts Pharma AG resolved to assume from Astellas Pharma Europe Ltd. the marketing authorisation for Dificlir tablets, a treatment for Clostridioides difficile infection, in Europe, the Middle East, Africa and the Commonwealth of Independent States, and entered into an asset transfer agreement dated 24 November 2020.」
Tillotts Pharma AG entered into an agreement to assume from Astellas Pharma Europe Ltd. the marketing rights for Dificlir tablets in the covered territories. The acquisition price is €109 million, and synergies with the existing product portfolio and an expanded presence in Europe are expected.